US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Onestream Inc

23.21

-0.6400-2.68%

Post-market: 23.670.4600+1.98%17:13 EDT

Volume:964.60K

Turnover:22.19M

Market Cap:4.09B

PE:-13.14

High:23.50

Open:23.35

Low:22.64

Close:23.85

Loading ...

Overview Company News Filings

Press Release: IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1

Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies

OneStream Splash to Usher in the Finance AI Era with Modern Finance Experience

Promethean's ActivPanel 10 Premium wins prestigious Red Dot Design Award 2025

OneStream to Participate in Upcoming Investor Conferences

OneStream Initiated at Outperform by Mizuho

Mizuho Securities Initiates Coverage on Onestream With Outperform Rating, $30 Price Target

MT Newswires Live

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups

GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST

KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer

Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OS/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","market":"US","secType":"STK","nameCN":"Onestream Inc","latestPrice":23.21,"timestamp":1754078400000,"preClose":23.85,"halted":0,"volume":964603,"hourTrading":{"tag":"盘后","latestPrice":23.67,"preClose":23.21,"latestTime":"17:13 EDT","volume":28092,"amount":652039.33866,"timestamp":1754082833706},"delay":0,"floatShares":69818472,"shares":176260091,"eps":-1.766751,"marketStatus":"Post-Mkt","change":-0.64,"latestTime":"08-01 18:32:48 EDT","open":23.35,"high":23.4999,"low":22.64,"amount":22189342.535403,"amplitude":0.036055,"askPrice":24,"askSize":225,"bidPrice":22.2,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-1.766751,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1754092800000},"marketStatusCode":4,"adr":0,"listingDate":1721793600000,"exchange":"NASDAQ","adjPreClose":23.85,"preHourTrading":{"tag":"盘前","latestPrice":23.69,"preClose":23.85,"latestTime":"09:03 EDT","volume":119,"amount":2747.738203,"timestamp":1754053425951},"postHourTrading":{"tag":"盘后","latestPrice":23.67,"preClose":23.21,"latestTime":"17:13 EDT","volume":28092,"amount":652039.33866,"timestamp":1754082833706},"volumeRatio":0.932395,"impliedVol":0.6863,"impliedVolPercentile":0.724},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","floatShares":69818472,"roa":"-35.83%","roe":"-108.78%","lyrEps":-1.232998,"volumeRatio":0.932395,"shares":176260091,"dividePrice":0,"high":23.4999,"amplitude":0.036055,"preClose":23.85,"low":22.64,"week52Low":16.6942,"pbRate":"9.91","psRate":"7.94","week52High":35.39,"institutionHeld":0,"latestPrice":23.21,"committee":-0.99115,"eps":-1.766751,"divideRate":0,"volume":964603,"delay":0,"ttmEps":-1.766751,"open":23.35,"prevYearClose":28.52,"prevWeekClose":25.01,"prevMonthClose":23.85,"prevQuarterClose":28.3,"fiveDayClose":25.01,"twentyDayClose":26.66,"sixtyDayClose":22.53,"earningDate":1754496000000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OS\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533950493","title":"Press Release: IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2533950493","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533950493?lang=en_us&edition=fundamental","pubTime":"2025-05-06 18:05","pubTimestamp":1746525900,"startTime":"0","endTime":"0","summary":"-- $1.05 billion of cash, cash equivalents and marketable securities as of. March 31, 2025, and an updated cash runway guidance into 2029; commercial. -- Over 300 patients enrolled in darovasertib and crizotinib registrational. 1L HLA-A2-negative MUM trial; targeting median PFS results by YE 2025 to. -- Successful FDA Type D meeting completed to finalize darovasertib Ph3. registrational trial design and received U.S. FDA Breakthrough Therapy. -- Targeting three darovasertib program clinical data updates at medical. conferences in 2025, including 1L MUM mOS results in >40 patients and. targeting clinical data update in over 40 SCLC patients at a medical. SOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the first quarter that ended March 31, 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4080","OS","PFS","R","BK4211","BK4097","BK4231","BK4139","BK4022","ADC","PB","BK4232","BK4195"],"gpt_icon":0},{"id":"2533458652","title":"Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1","url":"https://stock-news.laohu8.com/highlight/detail?id=2533458652","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533458652?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446400,"startTime":"0","endTime":"0","summary":"Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS <1. Mature overall survival data builds on encouraging high response rates with multiple complete responses. Patients with CPS <1 represent a high unmet medical need and have no available treatment options without chemotherapy. Meeting with FDA has now been requested to discuss next steps including potential paths to approval. Patients with CPS <1 in 1L HNSCC represent a treatment population with high unmet medical need. Up to 20% of 1L HNSCC patients have CPS <1 and despite immunotherapy’s progress in fighting cancer, anti-PD-1 therapy alone  is only approved for patients who express PD-L1 . Additionally, all available treatment options for patients with PD-L1 CPS <1 include chemotherapy.Importantly, efti in combination with pembrolizumab continues to be well-tolerated with no new safety signals. This safety and mature OS data build on","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immutep-efti-combination-keytruda-pembrolizumab-120000632.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["IE00BLSP4452.SGD","LU0265550359.USD","MRK","LU0106261372.USD","LU1291159041.SGD","LU1983299246.USD","SG9999014559.SGD","IE00BN8TJ469.HKD","IE00BFTCPJ56.SGD","LU0265550946.USD","LU1934455194.USD","IMM.AU","LU1057294990.SGD","LU2361044865.SGD","BK4139","LU0234572021.USD","OS","LU1093756325.SGD","BK7095","IE00BLSP4239.USD","LU1066053197.SGD","BK4533","LU0965509283.SGD","BK4007","APC.AU","BK4534","LU2112291526.USD","BK7508","LU0861579265.USD","CPS","LU1069347547.HKD","SG9999001176.USD","IE00BSNM7G36.USD","LU0070302665.USD","APC","LU0985320562.USD","IE00B4R5TH58.HKD","LU0211331839.USD","LU1496350171.SGD","LU2106854487.HKD","IE000M9KFDE8.USD","SG9999001176.SGD","LU2417539215.USD","LU0058720904.USD","LU2461242641.AUD","LU1941712264.USD","IMMP","LU1066051498.USD","LU2237443382.USD","IE0009355771.USD"],"gpt_icon":0},{"id":"2532882321","title":"Emmy-Winning Series Debuts Trailer for \"Shelter Me: The Cancer Pioneers\" Offering A Hopeful Look at Breakthrough Cancer Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2532882321","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532882321?lang=en_us&edition=fundamental","pubTime":"2025-05-02 21:32","pubTimestamp":1746192720,"startTime":"0","endTime":"0","summary":"LOS ANGELES, May 02, 2025----The official trailer for \"Shelter Me: The Cancer Pioneers\" has just dropped, giving audiences a moving first look at the groundbreaking new documentary that follows the emotional and inspiring journey of dogs helping to pioneer cancer treatments that are saving human lives. The movie will stream through the PBS app and on PBS.org starting on Thursday, May 15.\"This is one of the most powerful and consequential stories I’ve ever told,\" said Steven Latham, \"Shelter Me\" series Creator and Producer. \"Dogs are helping unlock the future of cancer treatment for people, and the results are incredibly promising.\". The official trailer captures the emotional stakes of the film: dogs that are beloved family members fighting cancer, dedicated and brave people, brilliant scientists and a future where hope comes on four legs. \"Shelter Me: The Cancer Pioneers\" is a powerful reminder of the unbreakable bond between humans and animals and how that relationship may hold the k","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/emmy-winning-series-debuts-trailer-133200780.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4231","BK4080","BK4097","DC","OS","BK4017","ADC","OSTX"],"gpt_icon":0},{"id":"2532070832","title":"OneStream Splash to Usher in the Finance AI Era with Modern Finance Experience","url":"https://stock-news.laohu8.com/highlight/detail?id=2532070832","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532070832?lang=en_us&edition=fundamental","pubTime":"2025-05-01 21:00","pubTimestamp":1746104400,"startTime":"0","endTime":"0","summary":"OneStream Splash and OneStream Wave unite for an immersive event packed with AI-driven innovation, technical collaboration and success stories from over 50 OneStream customers to transform finance. BIRMINGHAM, Mich., May 1, 2025 /PRNewswire/ -- OneStream,the leading enterprise Finance management platform that modernizes the Office of the CFO by unifying core financial and operational functions – including financial close, consolidation, reporting, planning and forecasting, today announces OneStream Splash, the company's flagship user conference, will take place May 13 – 15 at Music City Center in Nashville, TN.Finance leaders are under more pressure than ever to do more with less. They're expected to move faster, see further, and drive strategic decisions in real time—all while navigating complex systems, disconnected data, and resource constraints.At Splash, OneStream will reveal how AI solutions, purpose-built for Finance, are helping Finance teams navigate uncertainty and improve pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/onestream-splash-usher-finance-ai-130000676.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/onestream-splash-usher-finance-ai-130000676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0719512351.SGD","BK4612","LU0314104364.USD","SG9999014559.SGD","LU2092937221.SGD","LU2403377893.USD","BK4577","LU1235295455.SGD","LU2456880835.USD","LU0795875169.SGD","LU2092627202.USD","LU1429558221.USD","LU0072462426.USD","LU1548497426.USD","BK4527","LU0417517546.SGD","SG9999018857.SGD","LU2247934214.USD","LU1732800096.USD","LU0494093205.USD","IE00BWXC8680.SGD","LU2133065610.SGD","LU2237443622.USD","LU1435385759.SGD","LU1564329461.SGD","LU2360108059.USD","SG9999014567.USD","LU1983260115.SGD","LU1674673428.USD","LU1181866309.USD","LU1823568750.SGD","LU0689472784.USD","LU1244550221.USD","LU0823417737.USD","LU2347655156.SGD","LU1803068979.SGD","LU0289960550.SGD","LU0784385840.USD","LU0056508442.USD","OS","LU2764263203.CNY","LU1496350502.SGD","LU0950375773.USD","LU2250418816.HKD","LU2357305700.SGD","LU0345769128.USD","LU2463028550.USD","LU1244550577.SGD","LU1988902786.USD"],"gpt_icon":1},{"id":"2532770090","title":"Promethean's ActivPanel 10 Premium wins prestigious Red Dot Design Award 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2532770090","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532770090?lang=en_us&edition=fundamental","pubTime":"2025-05-01 20:30","pubTimestamp":1746102600,"startTime":"0","endTime":"0","summary":"SEATTLE, May 1, 2025 /PRNewswire/ --Promethean, a leading global tech company and brand owned by Mynd.ai, Inc. , took home the Red Dot Design Award 2025 for the ActivPanel 10 Premium, the company's next-generation interactive flat panel display .The Red Dot Design Award was established in 1955 and is one of the world's largest, most well-known design competitions. The independent Red Dot Jury assesses all entries based on four key principles of good design—the quality of function, seduction, use, and responsibility.In 2025, the jury consists of 43 experts from 21 countries, including designers, professors, journalists, and consultants from various disciplines. The ActivPanel 10 Premium won in the product design category, which seeks out products that achieve great design quality and a high degree of innovation.Promethean is a learning and collaboration technology company. From our founding in Blackburn, England, more than 25 years ago to our global operations serving 126 countries toda","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/prometheans-activpanel-10-premium-wins-123000753.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/prometheans-activpanel-10-premium-wins-123000753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MYND","BK4097","OS","BK4204"],"gpt_icon":0},{"id":"2532096018","title":"OneStream to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2532096018","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532096018?lang=en_us&edition=fundamental","pubTime":"2025-05-01 04:30","pubTimestamp":1746045000,"startTime":"0","endTime":"0","summary":"BIRMINGHAM, Mich., April 30, 2025 /PRNewswire/ -- OneStream, Inc. , the leading enterprise Finance management platform that modernizes the Office of the CFO by unifying core finance and operational functions -- including financial close, consolidation, reporting, planning and forecasting -- today announced that it will be presenting at the following investor conferences:. J.P. Morgan Global Technology, Media and Communications Conference on Wednesday, May 14, at 1:00 p.m. ET / 10:00 a.m. PT in Boston, MA.Bank of America Global Technology Conference on Tuesday, June 3, at 4:20 p.m. ET / 1:20 p.m. PT in San Francisco, CA.OneStream is how today's Finance teams can go beyond just reporting on the past and Take Finance Further by steering the business to the future. It's the leading enterprise finance platform that unifies financial and operational data, embeds AI for better decisions and productivity, and empowers the CFO to become a critical driver of business strategy and execution.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/onestream-participate-upcoming-investor-conferences-203000690.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/onestream-participate-upcoming-investor-conferences-203000690.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","BK4097"],"gpt_icon":0},{"id":"2531037114","title":"OneStream Initiated at Outperform by Mizuho","url":"https://stock-news.laohu8.com/highlight/detail?id=2531037114","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531037114?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:59","pubTimestamp":1746017940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 30, 2025 08:59 ET (12:59 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MFG","OS"],"gpt_icon":0},{"id":"2531034031","title":"Mizuho Securities Initiates Coverage on Onestream With Outperform Rating, $30 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2531034031","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531034031?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:10","pubTimestamp":1746015055,"startTime":"0","endTime":"0","summary":"Onestream (OS) has an average rating of Buy and mean price target of $31.16, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and r","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OS","MFG"],"gpt_icon":0},{"id":"2531303571","title":"BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified","url":"https://stock-news.laohu8.com/highlight/detail?id=2531303571","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531303571?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:30","pubTimestamp":1746012600,"startTime":"0","endTime":"0","summary":"Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 study. Biomarkers could be utilized to predict and provide better patient outcomes, including response rates and survival benefits. Positive delayed-type hypersensitivity   and a favorable Neutrophil-to-Lymphocyte Ratio   linked to longer progression-free survival  in Phase 3 patients. Presence of Circulating Tumor Cells  after patients’ initial Phase 3 treatment supports role as negative prognostic marker . Bria-IMT Phase 3 regimen was well-tolerated with a preferred tolerability profile. “Using biomarkers as powerful instruments to predict patient responsiveness to the Bria-IMT treatment would allow physicians and oncologists to identify potential responders sooner, providing better clinical outcomes and ultimately extending patients’ lives,” stated Carmen Calfa, MD, Clinical Research Lead for the breast site disease group at the University of Miami Miller School of Medicin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-reports-breaker-phase-3-113000083.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCTX","BK4139","BK4211","BCTXW","BCTXZ","OS","BK4606","DTH","NLR","BK4097","TPC","CAML","BK4195","PFS","BK4129"],"gpt_icon":0},{"id":"2531392850","title":"Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups","url":"https://stock-news.laohu8.com/highlight/detail?id=2531392850","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531392850?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:00","pubTimestamp":1746010800,"startTime":"0","endTime":"0","summary":"Statistically significant efficacy in biomarker subgroup analyses was observed:. 78% reduction in risk of death and 81% reduction in risk of progression or death in defined pretreatment ranges of serum or tumor CEACAM1 subgroup. 61% reduction is risk of death and 72% reduction in risk of progression or death in defined pretreatment ranges of serum CEACAM1 or myeloperoxidase  subgroup. 90% reduction is risk of death and 81% reduction in risk of progression or death in high tumor CEACAM1 and low PD-L1 combined positive score  subgroup. The biomarkers identified in the Phase 2 study are planned to be used for patient selection in the next Phase 2b study. Prolongation of 2.4 months in OS HR=0.81  and prolongation of 1.9 months in PFS HR=0.75  vs. control arm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/purple-biotech-reports-final-data-110000531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4613","LU2039709279.SGD","BK4560","BK4116","BK4554","BK4585","BK4588","BK4007","PPBT","LU0359201612.USD","01698","IE00B12V2V27.USD","IE00BYTNYN87.SGD","OS","BK4124","BK4108","CPS","BK4548","BK4552","BK4565","BK4563","BK4097","BK4509","ORR","BK4211","BK4195","SG9999011746.SGD","BK4535","LU2286300806.USD","PFS","BK4607","BK4571","BK4531","IE00BYQNZ168.SGD","NET","LU1023057109.AUD","TME","LU0359202008.SGD","BK4526"],"gpt_icon":0},{"id":"2531765670","title":"GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2531765670","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531765670?lang=en_us&edition=fundamental","pubTime":"2025-04-30 00:00","pubTimestamp":1745942400,"startTime":"0","endTime":"0","summary":"Advancing Gene-Directed Prodrug Therapy: Data Presented at AACR Supports Gedeptin's Potential in Solid Tumors. ATLANTA, GA - April 29, 2025  - GeoVax Labs, Inc. , a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of new clinical data on its gene-directed enzyme prodrug therapy, Gedeptin, at the American Association for Cancer Research  Annual Meeting 2025, being held April 2530 in Chicago, IL.The presentation, titled \"Viral-Vectored, Gene-Directed Prodrug Therapy  in Needle-Accessible Solid Tumors,\" was delivered by J. Marc Pipas, M.D., Executive Medical Director, Oncology at GeoVax, during the Phase II Clinical Trials 1 Poster Session on April 29, 2025. The session drew significant interest from researchers and clinicians, underscoring the growing recognition of Gedeptin's therapeutic potential. The corresponding abstract was published in the AACR journal Cancer Research.\"These clini","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-presents-gedeptin-r-clinical-160000847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2362541513.USD","BK4134","LU2517655291.USD","SD","BK4583","BK4097","BK4232","BK4213","OS","LU2517655374.HKD","BK4117","IT","AFG","PFS","LU0154245673.USD","BK4195","GOVXW","LU0154245756.USD","BK4588","BK4022","LU0107464264.USD","LU2362540622.SGD","LU2517655028.SGD","R","BK4585","LU2362541273.HKD","BK4211","GOVX","BK4139","LU1814569148.SGD","BK4107"],"gpt_icon":0},{"id":"2531759499","title":"Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2531759499","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531759499?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:00","pubTimestamp":1745935200,"startTime":"0","endTime":"0","summary":"An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer  who received AFM24 at 480 mg weekly demonstrates that higher drug exposure  leads to improved objective response rate  and longer progression free survival   without a negative impact on safety. These findings will be incorporated in future AFM24 trials to further improve efficacy outcomes of patients treated with AFM24. MANNHEIM, Germany, April 29, 2025  -- Affimed N.V. , a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented findings on an exposure-outcome analysis of its innate cell engager  AFM24, in patients with advanced or metastatic non-small cell lung cancer  in a poster session at the 2025 Annual Meeting of the American Association for Cancer Research .The analysis is based on post-hoc exposure-response data from 72 NSCLC patients treated with 480 mg of AFM24 monotherapy or a combination of AFM24 with atezolizumab. F","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/affimed-shows-higher-exposure-afm24-140000007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PK","BK4218","OS","BK4181","AFMD","BK4097","BK4139","ORR","BK4195","BK4211","PFS"],"gpt_icon":0},{"id":"2531816437","title":"Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2531816437","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531816437?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:45","pubTimestamp":1745923500,"startTime":"0","endTime":"0","summary":"Delivers Robust Earnings Performance, Successfully Navigating a Dynamic Environment. NEW YORK, April 29, 2025----Pfizer Inc.  reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance.\"Our overall solid first-quarter performance demonstrates our continued focus on commercial execution amid U.S. Medicare Part D headwinds. Our focus on operational efficiency and financial discipline is driving strong results to our bottom line. We are currently trending towards the upper end of our 2025 Adjusted diluted EPS guidance range.\". First-Quarter 2025 Revenues of $13.7 Billion, Reported Diluted EPS of $0.52, and Adjusted Diluted EPS of $0.92. On Track to Deliver Operating Margin Expansion from Ongoing Cost Realignment Program with Approximately $4.5 Billion of Net Cost Savings by End of 2025, and Announces Additional Productivity Gains Expected Through 2027 Leveraging Digital Enablement and Process Simplification. First Phase of Manufacturing Optimizatio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-reports-solid-first-quarter-104500122.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0234572021.USD","BK4585","ITT","BK4534","LU0054578231.USD","CDC","BK4195","BK4135","LU0225284248.USD","BK4533","PFE","LU1066051498.USD","LU1894683264.USD","BK4535","LU0053671581.USD","SOC","BK4548","IE0002270589.USD","BK4213","LU0170899867.USD","LU1066053197.SGD","BK4550","CAR","LU0225771236.USD","LU0058720904.USD","BCG","IE00B19Z3581.USD","SG9999002232.USD","LU0289739699.SGD","IE000M9KFDE8.USD","BK4230","LU0321505439.SGD","BK4599","BNTX","EC","LU1894683348.USD","SG9999013999.USD","LU0321505868.SGD","OS","BK4568","LU0868494617.USD","LU0122379950.USD","PFS","SG9999002224.SGD","LU1057294990.SGD","BK4022","IE00BLSP4452.SGD","SGXZ57979304.SGD","BK4581"],"gpt_icon":1},{"id":"2530147098","title":"BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2530147098","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530147098?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:30","pubTimestamp":1745839800,"startTime":"0","endTime":"0","summary":"Overall survival and clinical benefit in Phase 2 continue to outperform historical benchmarks, including very heavily pretreated patients. Clinical benefit observed in 83% of evaluable patient sub-group treated with the phase 3 formulation. Improved new Bria-OTS+ platform provides powerful innate and adaptive immune system activation. Title:Survival outcomes in a randomized phase 2 ofBria-IMT: An allogeneic whole cell cancer vaccineSession Title:Phase II and Phase III Clinical TrialsSession Start:4/28/2025 2:00 PM – 5:00 PM CSTLocation:Poster Section 50Poster Board Number:18Abstract Presentation Number:CT100. “We are thrilled to share impressive survival and clinical efficacy data at AACR on the advantages of using Bria-IMT plus checkpoint inhibitor in heavily treated patients who have failed multiple prior treatments, including ADCs and CPIs,” stated lead author, Saranya Chumsri, MD, Principal Investigator and Professor of Oncology, Mayo Clinic. “Treatment options have been limited fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-presents-benchmark-beating-survival-113000613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","OS","ORR","BCTX","BCTXZ","BK4139","BCTXW"],"gpt_icon":0},{"id":"2530040513","title":"Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST","url":"https://stock-news.laohu8.com/highlight/detail?id=2530040513","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530040513?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:30","pubTimestamp":1745839800,"startTime":"0","endTime":"0","summary":"– Phase 1 dose-escalation study to evaluate ziftomenib in combination with imatinib in patients with advanced GIST after imatinib failure –。– Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive and imatinib-resistant GIST preclinical models –。SAN DIEGO, April 28, 2025  -- Kura Oncology, Inc. , a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the first patients have been dosed in KOMET-015, a Phase 1 clinical trial of ziftomenib, the Company’s potent and selective, oral investigational menin inhibitor, in patients with advanced gastrointestinal stromal tumors  after imatinib failure.“Until now, most approaches to treating gastrointestinal stromal tumors rely on targeted KIT inhibition via tyrosine kinase inhibitors such as imatinib, however most patients eventually progress due to acquired secondary KIT mutations highlighting the need","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kura-oncology-announces-first-patients-113000397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PFS","AEIS","KURA","LU0300736492.USD","LU0300736062.USD","FTI","OS","IE00B19Z4B17.USD","BK4179","BK4505","IE00B7SZL793.SGD","LU0053671581.USD","ORR","BK4139","BK4157","IE00B66KJ199.SGD","LU0054578231.USD","IE0031619046.USD","BK4195","BK4097","IE00BD6J9T35.USD","BK4211"],"gpt_icon":0},{"id":"2530548354","title":"KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2530548354","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530548354?lang=en_us&edition=fundamental","pubTime":"2025-04-28 00:00","pubTimestamp":1745769600,"startTime":"0","endTime":"0","summary":"KEYNOTE-689 marks the first positive trial in more than two decades for patients with resected locally advanced head and neck squamous cell carcinoma . Results to be presented at American Association for Cancer Research  Annual Meeting 2025 during a Plenary Session and included in official meeting press program. \"As the first positive trial in over two decades for patients with resectable, locally advanced head and neck squamous cell carcinoma, the presentation of these landmark results marks an important moment for these patients and those who care for them,\" said Dr. Ravindra Uppaluri, the study’s co-principal investigator, director of Head and Neck Surgical Oncology, Brigham and Women’s Hospital and Dana-Farber","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/keytruda-pembrolizumab-perioperative-treatment-standard-160000135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2106854487.HKD","BTC","IE00B7SZL793.SGD","LU0320765646.SGD","MRK","ITT","LU1162221912.USD","LU1066051225.USD","LU0861579265.USD","BK4533","LU0054578231.USD","SGXZ57979304.SGD","ALT","LU2361044865.SGD","LU1430594728.SGD","LU2023250843.SGD","HSCT","AEIS","LU1854103824.USD","IE00BZ199S13.USD","CPS","OS","LU0289739699.SGD","RCC","SMP","IE0009355771.USD","SG9999001440.SGD","DM","BCG","LU0265550946.USD","LU1934455194.USD","HCC","SG9999014567.USD","BK4097","CRC","ON","BK4161","LU1861220033.SGD","CRT","LU0320765489.SGD","BK4135","LU2298322129.HKD","LU0208291251.USD","LU2361044949.HKD","BK4605","IE00BLSP4239.USD","LU1037948541.HKD","SOC","IE00BLSP4452.SGD","SG9999015358.SGD"],"gpt_icon":0},{"id":"2530175941","title":"Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2530175941","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530175941?lang=en_us&edition=fundamental","pubTime":"2025-04-27 01:50","pubTimestamp":1745689800,"startTime":"0","endTime":"0","summary":"Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response  with more than half of responders remaining cancer-free at one year after CR. Results reinforce potential of TAR-200 to transform outcomes for certain types of BCG-unresponsive, high-risk non-muscle invasive bladder cancer. As of March 2025, 82.4 percent of the 85 enrolled patients in the study achieved a complete response  , meaning their cancer was undetectable following treatment. This high response rate translated into sustained disease control, with 52.9 percent of responders maintaining complete response at one year. The median duration of response  was 25.8 months , indicating that many patients remained cancer-free for over two years without the need for reinduction therapy. At 12 months, 86.6 perc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/johnson-johnsons-tar-200-monotherapy-175000318.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/johnson-johnsons-tar-200-monotherapy-175000318.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0114720955.EUR","RC","LU2129689431.USD","JNJ","IE00BFTCPJ56.SGD","LU1894683264.USD","LU2592432038.USD","LU1023059063.AUD","LU0882574055.USD","LU1221951046.USD","LU1914381329.SGD","IE00B1BXHZ80.USD","IE000M9KFDE8.USD","LU0466842654.USD","LU1074936037.SGD","LU1718418525.SGD","IE00B7SZLL34.SGD","LU1929549753.HKD","LU2089984988.USD","LU1059921491.USD","LU2468319806.SGD","LU0792757196.USD","IE00B2B36J28.USD","BCG","LU1244550577.SGD","LU1061106388.HKD","LU1674673691.USD","LU0345769128.USD","LU2430703178.SGD","OS","CR","IE00B19Z3B42.SGD","SG9999002232.USD","LU2347655156.SGD","LU0234570918.USD","LU0345769631.USD","LU0203347892.USD","BK4504","IE00BLSP4239.USD","LU0795875086.SGD","IE00BDGV0183.EUR","BK4533","LU2505996509.AUD","IE00BN8TJ469.HKD","LU1244550221.USD","LU1066051811.HKD","LU1032955483.USD","LU0912757837.SGD","LU1244550494.USD"],"gpt_icon":0},{"id":"2530175929","title":"Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2530175929","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530175929?lang=en_us&edition=fundamental","pubTime":"2025-04-27 01:30","pubTimestamp":1745688600,"startTime":"0","endTime":"0","summary":"Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of care  Bacillus Calmette-Guérin  regimen compared to SOC alone. Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-nave, high-risk non-muscle invasive bladder cancer in more than 30 years. Results have been shared with global health authorities to support potential regulatory filings. \"New bladder cancer treatment options that help reduce rates of disease recurrence or progression are long overdue. Up to 50% of patients with high-risk non-muscle invasive bladder cancer may experience failure of BCG intravesical immunotherapy, yet it has been the standard of care after tumor resection for decades,\" said Neal Shore, M.D., FACS, Medical Director for START Carolina Research Center, and lead investigator ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-sasanlimab-combination-significantly-improves-173000786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0321505439.SGD","LU0122379950.USD","CR","LU1059921491.USD","LU1883839398.USD","SG9999011175.SGD","SOC","LU0170899867.USD","ADC","BK4585","LU1261432733.SGD","BK4550","PFE","SG9999001176.USD","BK4135","LU1023059063.AUD","SG9999003800.SGD","HR","IE000M9KFDE8.USD","SG9999002224.SGD","LU1894683348.USD","BK4592","BK4203","IE0002270589.USD","LU0456855351.SGD","LU1066053197.SGD","SG9999002232.USD","SG9999013999.USD","SGXZ57979304.SGD","BK4213","CI","LU1057294990.SGD","IE00BLSP4239.USD","BK4588","BK4581","IE00BSNM7G36.USD","BK4534","BK4007","LU0234572021.USD","BCG","OS","IE00BBT3K403.USD","BK4231","BK4097","LU0289739699.SGD","LU0985481810.HKD","LU0306806265.USD","BK4533","LU0225771236.USD"],"gpt_icon":1},{"id":"2530685901","title":"ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2530685901","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530685901?lang=en_us&edition=fundamental","pubTime":"2025-04-26 01:10","pubTimestamp":1745601000,"startTime":"0","endTime":"0","summary":"- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide  was well-tolerated and demonstrated promising anti-tumor activity. - Combination generated complete responses  in 83% of patients with indolent relapsed or refractory B-cell non-Hodgkin lymphoma  comparing favorably to 34% historical CR rate with R2 alone. - Phase 2 portion of trial in patients with previously untreated indolent NHL  is ongoing and has completed enrollment. After a median follow-up of 28 months  the two-year progression-free survival  rate was 69% and two-year overall survival  rate was 84%. Sixteen patients (80%) achieved complete responses and the best overall response rate  was 90%. As previously repo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alx-oncology-announces-encouraging-final-171000715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","ALX","BK4195","BK4211","BK4231","PFS","BK4139","BK4097","CR","SMP","BK4161","BK4080","ORR","BK4124","ALXO"],"gpt_icon":0},{"id":"2530513653","title":"ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2530513653","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530513653?lang=en_us&edition=fundamental","pubTime":"2025-04-25 21:00","pubTimestamp":1745586000,"startTime":"0","endTime":"0","summary":"In ASPEN-03 and ASPEN-04 trials, efficacy data do not support advancing evorpacept in combination with Merck’s anti-PD-1 therapy, KEYTRUDA , into a registrational study. Company remains confident in continuing to pursue evorpacept in multiple clinical trials, based on the different mechanism of evorpacept in combination with anti-cancer antibodies, as evidenced by durable clinical response and consistent safety data in prior clinical trials. In the ASPEN-03 and ASPEN-04 clinical trials, evorpacept was combined with pembrolizumab with or without chemotherapy to investigate a second and distinct mechanism of action. This discrete approach explored the concept that evorpacept may enhance T-cell priming by activating dendritic cells and stimulating the adaptive immune system. The trial outcomes were not sufficiently supportive of advancing evorpacept in combination with pe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alx-oncology-reports-aspen-03-130000813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1934455277.USD","PFS","LU1934455194.USD","LU2461242641.AUD","LU2089984988.USD","LU2468319806.SGD","IE00B1BXHZ80.USD","LU1066051811.HKD","LU1069347547.HKD","LU1037948541.HKD","LU1989772840.SGD","LU0234572021.USD","BK4516","LU1974910355.USD","LU0965509283.SGD","SG9999014542.SGD","SG9999014567.USD","LU0965508806.USD","ALX","IE000M9KFDE8.USD","LU1093756325.SGD","BK4080","LU1037948897.HKD","LU1116320737.USD","IE00BN8TJ469.HKD","LU1291159041.SGD","LU1934455863.HKD","LU2106854487.HKD","SG9999014559.SGD","MRK","ORR","IE0002141913.USD","OS","LU0211331839.USD","ALXO","LU1116320901.HKD","BK4097","IE00B2B36J28.USD","LU0203345920.USD","LU1917777945.USD","IE00BFTCPJ56.SGD","LU0265550946.USD","LU0861579265.USD","LU1057294990.SGD","LU1941712264.USD","LU1983299246.USD","BK4231","SG9999001176.USD","LU1035773651.USD","BK4550"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":191,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OS\",params:#limit:5,,,undefined,":[{"date":"2025-08-07","symbol":"OS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/06","expectedEps":0.01,"defaultRemindTime":1754596800000,"name":null,"time":"Post Market","dateTimestamp":1754539200000,"actualEps":null},{"market":"US","date":"2025-05-08","symbol":"OS","fiscalQuarterEnding":"2025/03","expectedEps":-0.03,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":0.04},{"market":"US","date":"2025-02-11","symbol":"OS","fiscalQuarterEnding":"2024/12","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739250000000,"reportTimeType":"post","actualEps":0.07},{"market":"US","date":"2024-11-07","symbol":"OS","fiscalQuarterEnding":"2024/09","expectedEps":0,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-1.06},{"market":"US","date":"2024-09-03","symbol":"OS","fiscalQuarterEnding":"2024/06","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1725336000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.5714,"hold":0.0952,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":21,"updateTime":1753329600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OS","date":"2025-07-31","current":-18.573174,"percent":0.82996,"low":-1655.61542,"twenty":-429.42237,"median":-25.973452,"eighty":-18.729012,"high":-14.493656,"avg":-321.840777,"sd":559.1869,"marketCap":4369487655},"quantilePoints":[{"date":"2024-08-02","current":-402.058638,"twenty":-402.058638,"median":-402.058638,"eighty":-402.058638,"marketCap":4348264172},{"date":"2024-08-09","current":-394.529993,"twenty":-398.004752,"median":-394.602383,"eighty":-391.489578,"marketCap":4266841869},{"date":"2024-08-16","current":-420.156344,"twenty":-402.058638,"median":-395.977809,"eighty":-394.529993,"marketCap":4543990864},{"date":"2024-08-23","current":-418.563746,"twenty":-420.156344,"median":-400.248867,"eighty":-394.674774,"marketCap":4526766915},{"date":"2024-08-30","current":-439.701867,"twenty":-427.829772,"median":-415.668113,"eighty":-395.977809,"marketCap":4755375690},{"date":"2024-09-06","current":-1412.285699,"twenty":-434.093948,"median":-420.156344,"eighty":-395.977809,"marketCap":4652069092},{"date":"2024-09-13","current":-1421.532228,"twenty":-630.517125,"median":-426.381956,"eighty":-397.599363,"marketCap":4682527160},{"date":"2024-09-20","current":-1491.611188,"twenty":-1406.835113,"median":-428.55368,"eighty":-398.352228,"marketCap":4913367253},{"date":"2024-09-27","current":-1641.015636,"twenty":-1479.542034,"median":-435.672004,"eighty":-401.33473,"marketCap":5405505506},{"date":"2024-10-04","current":-1582.129844,"twenty":-1582.616503,"median":-445.348351,"eighty":-408.313205,"marketCap":5211535706},{"date":"2024-10-11","current":-1384.546111,"twenty":-1557.991535,"median":-1361.673117,"eighty":-414.50986,"marketCap":4560694889},{"date":"2024-10-18","current":-1422.505547,"twenty":-1506.405635,"median":-1387.466067,"eighty":-417.984619,"marketCap":4685733272},{"date":"2024-10-25","current":-1513.510863,"twenty":-1501.052381,"median":-1410.582391,"eighty":-419.837824,"marketCap":4985504782},{"date":"2024-10-31","current":-1488.204572,"twenty":-1545.825049,"median":-1419.58559,"eighty":-422.588676,"marketCap":4902145859},{"date":"2024-11-08","current":-29.444986,"twenty":-1544.267739,"median":-1421.532228,"eighty":-422.588676,"marketCap":5359016876},{"date":"2024-11-15","current":-29.547337,"twenty":-1525.190689,"median":-1414.232336,"eighty":-406.749563,"marketCap":5377644907},{"date":"2024-11-22","current":-27.361909,"twenty":-1504.167001,"median":-1405.472467,"eighty":-395.977809,"marketCap":4979894851},{"date":"2024-11-29","current":-26.339693,"twenty":-1496.769778,"median":-1384.546111,"eighty":-392.705744,"marketCap":4793850470},{"date":"2024-12-06","current":-28.33551,"twenty":-1493.655158,"median":-903.058146,"eighty":-29.829328,"marketCap":5157091209},{"date":"2024-12-13","current":-28.454992,"twenty":-1490.248542,"median":-439.701867,"eighty":-28.749622,"marketCap":5178836972},{"date":"2024-12-20","current":-27.223413,"twenty":-1484.895288,"median":-431.521704,"eighty":-28.258307,"marketCap":4954688343},{"date":"2024-12-27","current":-27.048786,"twenty":-1479.834029,"median":-428.191726,"eighty":-28.004145,"marketCap":4922906075},{"date":"2025-01-03","current":-25.973452,"twenty":-1479.444702,"median":-426.381956,"eighty":-27.732022,"marketCap":4727194212},{"date":"2025-01-10","current":-24.227183,"twenty":-1479.444702,"median":-422.183287,"eighty":-27.252823,"marketCap":4409371530},{"date":"2025-01-17","current":-26.460569,"twenty":-1468.54353,"median":-415.668113,"eighty":-26.869269,"marketCap":4815850013},{"date":"2025-01-24","current":-27.894348,"twenty":-1465.818237,"median":-402.058638,"eighty":-26.861301,"marketCap":5076799163},{"date":"2025-01-31","current":-27.407231,"twenty":-1462.314289,"median":-396.991281,"eighty":-26.925021,"marketCap":4988143362},{"date":"2025-02-07","current":-27.09474,"twenty":-1459.102337,"median":-394.674774,"eighty":-26.925021,"marketCap":4931269830},{"date":"2025-02-14","current":-19.646244,"twenty":-1457.642359,"median":-390.041762,"eighty":-26.782239,"marketCap":4247537655},{"date":"2025-02-21","current":-19.437413,"twenty":-1455.695721,"median":-30.305187,"eighty":-26.72172,"marketCap":4202388031},{"date":"2025-02-28","current":-18.385222,"twenty":-1452.094441,"median":-29.520901,"eighty":-26.562732,"marketCap":3974903390},{"date":"2025-03-07","current":-18.486889,"twenty":-1446.059864,"median":-28.777108,"eighty":-26.339693,"marketCap":3996883783},{"date":"2025-03-14","current":-16.449855,"twenty":-1440.122619,"median":-28.454992,"eighty":-26.179328,"marketCap":3556475076},{"date":"2025-03-21","current":-17.921046,"twenty":-1437.981318,"median":-28.198548,"eighty":-25.317223,"marketCap":3874548031},{"date":"2025-03-28","current":-18.76981,"twenty":-1430.38943,"median":-27.986257,"eighty":-24.094834,"marketCap":4058051659},{"date":"2025-04-04","current":-16.296269,"twenty":-1422.116219,"median":-27.889753,"eighty":-20.198845,"marketCap":3523269657},{"date":"2025-04-11","current":-15.87621,"twenty":-1419.974918,"median":-27.820821,"eighty":-19.520945,"marketCap":3432452458},{"date":"2025-04-17","current":-15.802935,"twenty":-1417.346957,"median":-27.682957,"eighty":-19.180725,"marketCap":3416610370},{"date":"2025-04-25","current":-17.317281,"twenty":-1415.400319,"median":-27.425612,"eighty":-18.846182,"marketCap":3744013527},{"date":"2025-05-02","current":-17.960471,"twenty":-1411.604376,"median":-27.370467,"eighty":-18.532156,"marketCap":3883071858},{"date":"2025-05-09","current":-18.233962,"twenty":-1408.19776,"median":-27.329108,"eighty":-18.405555,"marketCap":4289685457},{"date":"2025-05-16","current":-21.240398,"twenty":-1401.871187,"median":-27.223413,"eighty":-18.515128,"marketCap":4996973579},{"date":"2025-05-23","current":-21.307828,"twenty":-1386.882076,"median":-27.071763,"eighty":-18.645114,"marketCap":5012836988},{"date":"2025-05-30","current":-20.970679,"twenty":-1384.546111,"median":-26.979854,"eighty":-18.713226,"marketCap":4933519947},{"date":"2025-06-06","current":-21.779837,"twenty":-1366.053052,"median":-26.837395,"eighty":-18.714534,"marketCap":5123880845},{"date":"2025-06-13","current":-21.083062,"twenty":-1357.293182,"median":-26.745487,"eighty":-18.76981,"marketCap":4959958960},{"date":"2025-06-20","current":-21.397734,"twenty":-630.517125,"median":-26.722672,"eighty":-18.799724,"marketCap":5033988198},{"date":"2025-06-27","current":-20.715944,"twenty":-446.043303,"median":-26.635196,"eighty":-18.835877,"marketCap":4873591516},{"date":"2025-07-03","current":-19.974216,"twenty":-441.960461,"median":-26.551186,"eighty":-18.852455,"marketCap":4699094026},{"date":"2025-07-11","current":-19.329886,"twenty":-438.862005,"median":-26.400131,"eighty":-18.891318,"marketCap":4547510347},{"date":"2025-07-18","current":-18.603142,"twenty":-435.145985,"median":-26.322706,"eighty":-18.792246,"marketCap":4376538059},{"date":"2025-07-25","current":-18.767971,"twenty":-431.217662,"median":-26.184843,"eighty":-18.769074,"marketCap":4415315279},{"date":"2025-07-31","current":-18.573174,"twenty":-429.42237,"median":-25.973452,"eighty":-18.729012,"marketCap":4369487655}],"updateTime":1754062270070}}}